|本期目录/Table of Contents|

[1]王海,冷冬妮,石群立,等.基底细胞样乳腺癌临床病理研究[J].医学研究与战创伤救治(原医学研究生学报),2009,11(04):293-297.
　WANG Hai,LENG Dong-ni,SHI Qun-li,et al.A Clinicopathological study of basal-like breast carcinoma[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2009,11(04):293-297.
点击复制

基底细胞样乳腺癌临床病理研究()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第11卷
期数:
2009年04期
页码:
293-297
栏目:
出版日期:
2009-07-20

文章信息/Info

Title:
A Clinicopathological study of basal-like breast carcinoma
文章编号:
1672-271X(2009)04-0293-05
作者:
王海1; 冷冬妮2; 石群立1 ; 周航波1; 姜少军1; 杜军1; 周晓军1
1. 南京军区南京总医院病理科，江苏南京210002；2. 解放军第454医院病理科，江苏南京210002
Author(s):
WANG Hai1;  LENG Dong-ni2;  SHI Qun-li1;  ZHOU Hang-bo1;  JIANG Shao-jun1;  DU Jun1;  ZHOU Xiao-jun1
1. Department of Pathology, Nanjing General Hospital of Nanjing Military Command, PLA, Nanjing 210002, China; 2. Department of Pathology, the 454 Hospital of PLA, Nanjing 210002, China
关键词:
乳腺; 基底细胞样癌; 免疫组化; 超微结构
Keywords:
Breast;  Basal-like carcinoma;  Immunohistochemistry;  Ultrastructure
分类号:
R730.267.1
DOI:
-
文献标志码:
A
摘要:
目的 研究基底细胞样乳腺癌的临床病理特点，并分析其免疫组化及超微结构特征。方法采用HE、免疫组化(EnVision法)及电镜技术观察12例基底细胞样乳腺癌。结果12例患者均为女性，年龄35～73岁，中位年龄54岁。肿瘤直径2.4～3 cm，无包膜。组织学上肿瘤组织具有推进式的边缘，周围伴淋巴细胞浸润。瘤细胞呈合体细胞样，通常见坏死。所有病例显示为高级别癌，核分裂象易见。4例发生淋巴结转移。免疫组化:ER、PR和HER2均阴性，CK5/6 12例阳性，CK14 阳性9例，EGFR阳性10例。电镜示肿瘤细胞有异型性，胞质内可见张力原纤维丝。结论基底细胞样型乳腺癌具有独特的组织学与免疫表型特征，EGFR蛋白常过度表达，对于EGFR分子靶向治疗可能有效。
Abstract:
ObjectiveTo study the clinicopathological features of basal-like breast carcinoma and to analyze their immunohistochemical and ultrastructural features. Methods12 cases of basal-like breast carcinoma were investigated with HE staining, EnVision immunostaining and electron microscopy. ResultsAll patients were females, 35~73 years in age (median 54 years). The tumors were 2.4~3 cm in diameter, none encapsulated. Histologically，tumors had pushing margins with a peri-tumoural lymphocytic infiltrate and had a syncytial growth pattern. They often showed areas of necrosis .All cases were high grade with a very high mitotic index. 4 cases had nodal metastases. Immunohistochemically , the tumors were negative for ER，PR and HER2, whereas positive for CK5/6 (12 cases), CK14 (9 cases) and EGFR (10 cases). Ultrastructure showed the cells of tumors were heteromorphism, tonofibril in intracytoplasm. ConclusionBasal-like breast carcinoma has unique histological and immunohistochemical features. The EGFR protein is often overexpressed in this subtype, so patients might benefit from treatment with anti-EGFR drugs.

参考文献/References:

[1]Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours [J]. Nature, 2000, 406(6797):747-752.
[2]Tavassoli FA, Devilee P. World Health Organization Classification of Tumours.Pathology and Genetics of Tumours of the Breast and Female Genital Organs[M]. Lyon:IARC Press,2003:10-12.
[3] Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma [J]. Clin Cancer Res, 2004,10(16):5367-5374.
[4]Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review[J]. J Clin Oncol, 2008, 26(15):2568-2581.
[5]Fulford LG, Reis-Filho JS, Ryder K, et al. Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival[J]. Breast Cancer Res, 2007, 9(1):R4.
[6]Millikan RC, Newman B, Tse CK, et al. Epidemiology of basal-like breast cancer [J]. Breast Cancer Res Treat, 2008,109(1):123-139.
[7]Yang X, Sherman M, Rimm D, et al. Differences in risk factors for breast cancer molecular subtypes in a population-based study[J]. Cancer Epidemiol Biomarkers Prev, 2007,16(3):439-443.
[8]Rakha EA, Putti TC, Abd El-Rehim DM, et al. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation [J]. J Pathol, 2006, 208(4):495-506.
[9]Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma [J]. Mod Pathol, 2006,19(2):264-271.
[10]Potemski P, Kusinska R, Watala C, et al. Prognostic relevance of basal cytokeratin expression in operable breast cancer[J]. Oncology, 2005,69(6):478-485.
[11]Matos I, Dufloth R, Alvarenga M, et al. p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas[J]. Virchows Arch，2005,447(4):688-694.
[12]Lerma E, Peiro G, Ramon T, et al. Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas) [J]. Mod Pathol, 2007, 20(11):1200-1207.
[13]张庆慧，徐嘉雯．提高对基底细胞样乳腺癌和三阴性乳腺癌的认识[J]．临床与实验病理学杂志，2008，24(2):131-136．
[14]Bhargava R, Gerald WL, Li AR, et al. EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER2 status and absence of EGFR-activating mutations [J]. Mod Pathol, 2005, 18(8):1027-1033.
[15]Jumppanen M, Gruvberger-Saal S, Kauraniemi P, et al. Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers[J]. Breast Cancer Res,2007，9(1):R16.

相似文献/References:

备注/Memo

备注/Memo:
-
更新日期/Last Update: 2013-11-20